Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Am J Clin Nutr. 2023 Aug;118(2):391-405. doi: 10.1016/j.ajcnut.2023.05.012. Epub 2023 Jun 23.
Serving whey protein before a meal in order to lower postprandial blood glucose concentrations is known as a premeal. The underlying mechanisms are only partly understood but may involve stimulation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and insulin secretion together with a slower gastric emptying rate.
The objective of this systematic review and meta-analysis was to review all randomized clinical trials investigating premeals with whey protein in comparison with a nonactive comparator (control) that evaluated plasma glucose, GLP-1, GIP, insulin, and/or gastric emptying rate. Secondary aims included subgroup analyses on the timing and dose of the premeal together with the metabolic state of the participants [lean, obese, and type 2 diabetes mellitus (T2DM)].
We searched EMBASE, CENTRAL, PUBMED, and clinicaltrials.gov and found 16 randomized crossover trials with a total of 244 individuals. The last search was performed on 9 August, 2022.
Whey protein premeals lowered peak glucose concentration by -1.4 mmol/L [-1.9 mmol/L; -0.9 mmol/L], and the area under the curve for glucose was -0.9 standard deviation (SD) [-1.2 SD; -0.6 SD] compared with controls (high certainty). In association with these findings, whey protein premeals elevated GLP-1 (low certainty) and peak insulin (high certainty) concentrations and slowed gastric emptying rate (high certainty) compared with controls. Subgroup analyses showed a more pronounced and prolonged glucose-lowering effect in individuals with T2DM compared with participants without T2DM. The available evidence did not elucidate the role of GIP. The protein dose used varied between 4 and 55 g, and meta-regression analysis showed that the protein dose correlated with the glucose-lowering effects.
In conclusion, whey protein premeals lower postprandial blood glucose, reduce gastric emptying rate, and increase peak insulin. In addition, whey protein premeals may elevate plasma concentrations of GLP-1. Whey protein premeals may possess clinical potential, but the long-term effects await future clinical trials.
在餐前摄入乳清蛋白以降低餐后血糖浓度的方法被称为餐前服用。其潜在机制尚未完全阐明,但可能涉及刺激胰高血糖素样肽-1(GLP-1)、葡萄糖依赖性胰岛素释放多肽(GIP)和胰岛素的分泌,同时减缓胃排空速度。
本系统评价和荟萃分析的目的是回顾所有比较乳清蛋白餐前服用与非活性对照(对照)的随机临床试验,评估血浆葡萄糖、GLP-1、GIP、胰岛素和/或胃排空率。次要目标包括对餐前服用的时间和剂量以及参与者的代谢状态(瘦、胖和 2 型糖尿病(T2DM))进行亚组分析。
我们检索了 EMBASE、CENTRAL、PUBMED 和 clinicaltrials.gov,并找到了 16 项随机交叉试验,共有 244 人参与。最后一次搜索是在 2022 年 8 月 9 日进行的。
与对照组相比,乳清蛋白餐前服用可使峰值血糖浓度降低-1.4mmol/L[-1.9mmol/L;-0.9mmol/L],血糖曲线下面积降低-0.9 标准差(SD)[-1.2SD;-0.6SD](高确定性)。与此相关,乳清蛋白餐前服用可升高 GLP-1(低确定性)和峰值胰岛素(高确定性)浓度并减缓胃排空率(高确定性)。亚组分析显示,与非 T2DM 参与者相比,T2DM 患者的降糖效果更为显著和持久。现有证据并未阐明 GIP 的作用。所使用的蛋白质剂量在 4 至 55 克之间,元回归分析表明蛋白质剂量与降糖效果相关。
总之,乳清蛋白餐前服用可降低餐后血糖,降低胃排空率,增加峰值胰岛素。此外,乳清蛋白餐前服用可能会升高血浆 GLP-1 浓度。乳清蛋白餐前服用可能具有临床潜力,但长期效果有待未来临床试验证实。